Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
14JUN

FCA names eight firms in AI Live Testing round two

3 min read
16:35UTC

Two startups, five incumbents, one Swiss bank, and one technical partner: the FCA's AI sandbox is starting to look like institutional infrastructure rather than a pilot.

← Back to London startup raises Britain's own AI modelJump to analysis ↓
TechnologyDeveloping
Key takeaway

FCA sandbox demand has surged and AI assurance methodology is crystallising around a single London vendor.

The Financial Conduct Authority (FCA) named its second AI Live Testing cohort on 21 April 2026: Aereve, Coadjute, Barclays, Experian, GoCardless, Lloyds Banking Group via Scottish Widows, UBS, and Palindrome. London AI-assurance startup Advai joined as technical partner, providing the cohort's evaluation methodology. Cohort evaluation lands in Q1 2027.

AI Live Testing sits inside the broader FCA Regulatory Sandbox, the programme that lets authorised firms test products in live market conditions under conditional permissions. Applications to the wider sandbox are up 49% year on year, the highest volume since the Innovation Hub launched in 2016. The cohort mix is deliberately bimodal: incumbent banks (Barclays, Lloyds, UBS) are testing AI against the same framework as challenger and startup firms (Aereve, Coadjute, Palindrome), with Advai's assurance methodology applied across both tiers. The regulator wants a single evidence base covering customer-risk AI models at both incumbent and challenger scale.

The composition reveals the sandbox's new centre of gravity. Experian brings credit-scoring models; GoCardless brings payment-fraud detection; the Lloyds/Scottish Widows participation targets life and pensions AI; UBS brings wealth-management use cases. Advai is the only dedicated AI-assurance vendor in the picture, which means its methodology will set the de facto evaluation standard for the cohort's output.

Innovate UK's shift to a DARPA-style portfolio model and the FCA's AI Live Testing expansion are parallel moves toward active programme management rather than passive competition windows. For UK fintech founders, the Q1 2027 evaluation is the date to track; the results will either unlock a faster authorisation path for AI in regulated finance or expose the structural gap between what the regulator can assess and what firms are actually shipping.

Deep Analysis

In plain English

The FCA (Financial Conduct Authority) is the UK body that regulates banks and financial companies. It runs a programme where it lets companies test new AI tools inside a controlled environment, with special regulatory permissions, before allowing them into the full market. This week it named eight organisations for its second batch of companies going through that process; a mix of big banks like Barclays and Lloyds, and smaller tech firms. The 49% jump in applications to join the programme suggests a lot more financial companies are building AI products and want regulatory approval to use them.

Deep Analysis
Root Causes

The EU AI Act's financial services provisions, which came into force in stages from August 2024, created a regulatory divergence that UK-authorised firms must navigate: EU-passported services now require AI system classification under EUAIA rules, while UK-only activities face a principles-based FCA framework without equivalent statutory classification requirements. The FCA AI Live Testing programme is the UK's pre-statutory response; building an evidence base before legislation is necessary.

Advai's selection as technical partner; rather than an established firm like Accenture or PwC; reflects the FCA's intent to validate a startup-led AI assurance market; if Advai's methodology is endorsed by the FCA's Q1 2027 evaluation report, it becomes a de facto standard that fintech founders must reference in their own AI governance documentation.

What could happen next?
  • Consequence

    Advai's endorsement as FCA technical partner will generate commercial demand for its AI assurance methodology from all firms seeking FCA AI-related authorisation after Q1 2027, regardless of whether they were in the cohort; expect Advai to raise a Series A within 12 months of the evaluation report's publication.

  • Risk

    If the FCA's Q1 2027 'good and poor practice' report finds that incumbent-bank AI deployments outperform startup ones on safety metrics, it will create a precedential bias in FCA authorisation decisions that disadvantages fintech challengers in AI-enabled credit and payments applications.

Sources:CNBC
Mentions:Financial Conduct Authority →Aereve →Coadjute →Lloyds Banking Group →Scottish Widows →UBS →Palindrome →Advai →Innovate UK →PISCES →AI Live Testing →Barclays →EU AI Act →
First Reported In

Update #2 · Britain's innovation pipe leaks at both ends

CNBC· 22 Apr 2026
Read original →
Causes and effects
This Event
FCA names eight firms in AI Live Testing round two
FCA Regulatory Sandbox applications are up 49% year on year, the clearest regulator-side signal yet that UK fintech formation is running hot into Q2 2026.
Led to
FCA puts Revolut in stablecoin sandbox
The FCA's stablecoin sandbox and second AI Lab cohort follow the first AI Live Testing intake in April 2026, continuing the regulator's drive to thin the rulebook.
Occurred 8 Jun 2026
Read story →
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.